Authorities have raised concerns about counterfeit injection pens falsely labelled as Ozempic, a widely used diabetes drug that gained attention on social media for its perceived weight loss benefits. Ozempic, designed for once-weekly injections to treat type 2 diabetes, has faced increased demand and stock shortages due to its off-label use for weight loss.
The European Medicines Agency (EMA) reported the discovery of fake pre-filled pens in the EU and UK, originating from wholesalers in Austria and Germany. The labels on the counterfeit pens are in German. France’s ANSM medicines authority has urged vigilance throughout the supply chain as a precaution.
While there is currently no evidence of harm to patients from these falsified medicines dispensed through legal pharmacies, authorities are actively investigating the issue. The German drug regulator, BfArM, released images highlighting the notable differences between the counterfeit and authentic Ozempic pens, with inactive serial numbers being a key identifying factor.
The active ingredient in Ozempic, semaglutide, has gained approval in the EU and UK for weight loss under the brand name Wegovy. Both products are produced by the Danish pharmaceutical group Novo Nordisk, which has experienced increased profits due to the drug’s demand.
This development comes amidst recent warnings from researchers about the class of drugs known as GLP-1 agonists, which includes Ozempic. The drugs Rybelsus and Saxenda were also mentioned in connection with a heightened risk of severe gastrointestinal problems, including stomach paralysis. Researchers emphasise the importance of taking these drugs only under the prescription and supervision of healthcare professionals.
